American Association for Cancer Research
23266066cir140083-sup-131049_1_supp_0_nd14xx.docx (41.34 kB)

Supplementary Tables 1 - 3, Methods, Figure Legends from c-Abl Modulates Tumor Cell Sensitivity to Antibody-Dependent Cellular Cytotoxicity

Download (41.34 kB)
journal contribution
posted on 2023-04-03, 22:41 authored by Joseph C. Murray, Dalal Aldeghaither, Shangzi Wang, Rochelle E. Nasto, Sandra A. Jablonski, Yong Tang, Louis M. Weiner

Supplementary Table 1. Gene symbol and target sequences for two pooled siRNAs used in primary screens. Supplementary Table 2. Gene symbols and target sequences for four individual siRNAs utilized in secondary screens. Supplementary Table 3. Gene symbols and QuantiTect Primer Assays (Qiagen) used for quantitative reverse-transcription PCR (Q-RT-PCR) assessments.



Monoclonal antibodies (mAb) can modulate cancer cell signal transduction and recruit antitumor immune effector mechanisms—including antibody-dependent cellular cytotoxicity (ADCC). Although several clinically effective antibodies can promote ADCC, therapeutic resistance is common. We hypothesized that oncogenic signaling networks within tumor cells affect their sensitivity to ADCC. We developed a screening platform and targeted 60 genes derived from an EGFR gene network using RNAi in an in vitro ADCC model system. Knockdown of GRB7, PRKCE, and ABL1 enhanced ADCC by primary and secondary screens. ABL1 knockdown also reduced cell proliferation, independent of its ADCC enhancement effects. c-Abl overexpression decreased ADCC sensitivity and rescued the effects of ABL1 knockdown. Imatinib inhibition of c-Abl kinase activity also enhanced ADCC—phenocopying ABL1 knockdown—against several EGFR-expressing head-and-neck squamous cell carcinoma cell lines by ex vivo primary natural killer cells. Our findings suggest that combining c-Abl inhibition with ADCC-promoting antibodies, such as cetuximab, could translate into increased therapeutic efficacy of mAbs. Cancer Immunol Res; 2(12); 1186–98. ©2014 AACR.